| Literature DB >> 36228027 |
Luiz Henrique Gonçalves Maciel1, Cosmo Vieira da Rocha Neto2, Yasmin Ferreira Martins2, Francielen de Azevedo Furtado3, Pâmela Cunha Teixeira3, Maianne Yasmin Oliveira Dias1, Yanka Karolinna Batista Rodrigues1, Isa Cristina Ribeiro Piauilino1, Sérgio Damasceno Pinto3, Aline Cristiane Côrte Alencar3, João Bosco de Lima Gimaque3, Maria Paula Gomes Mourão3,4, Marcus Vinicius Guimarães Lacerda1,3,5, Márcia da Costa Castilho3, Camila Bôtto-Menezes1,3,4.
Abstract
BACKGROUND: In the clinical course of diseases such as arboviruses, skin rashes may appear, as is often seen in other infectious diseases. The aim of this study was to estimate the prevalence of arboviruses and other infectious causes of skin rash in a tertiary health unit in Manaus, Amazonas state, Western Brazilian Amazon. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2022 PMID: 36228027 PMCID: PMC9560595 DOI: 10.1371/journal.pntd.0010727
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Flowchart of inclusion of patients treated at FMT-HVD for skin rash.
Baseline and clinical characteristics of patients with rash, FMT-HVD, Manaus, February 2018 to May 2019.
| Characteristics | Total (N = 340) | |
|---|---|---|
| n (%) or Mean ± SD | ||
|
| 36.5 ± 12.2 | |
| 18 to 40 | 226 (66.5) | |
| 41 to 59 | 99 (29.1) | |
| ≥ 60 | 15 (4.4) | |
|
| Male | 112 (39.9) |
| Female | 228 (67.1) | |
|
| White | 40 (11.8) |
| Black | 3 (0.9) | |
| Brown | 293 (86.2) | |
| Indigenous | 1 (0.3) | |
| Other | 3 (0.9) | |
|
| 3.9 ± 2.4 | |
| 0 to 2 | 103 (30.3) | |
| 3 to 5 | 163 (47.9) | |
| 6 to 8 | 64 (18.8) | |
| ≥ 9 | 10 (3.0) | |
|
| Maculopapular rash | 305 (90.5) |
| Pruritus | 298 (87.6) | |
| Fever | 172 (50.6) | |
| Edema | 215 (63.2) | |
| Arthralgia | 243 (71.5) | |
| Conjunctival hyperemia | 191 (57.2) | |
aMean ± standard deviation.
bDays from the onset of symptoms until medical attention and collection of laboratory specimens. Minimum value: 1 day of symptom; maximum value: 17 days of symptoms.
Baseline and clinical characteristics of patients with Zika infection and other infectious causes of rash, FMT-HVD, Manaus, February 2018 to May 2019.
| Characteristics | Zika positive (N = 222) | Other infections | ||
|---|---|---|---|---|
| n (%) or Mean ± SD | n (%) or Mean ± SD | |||
|
| 38.4 ± 12.2 | 29.1 ± 7.3 | 0.001 | |
|
| 18 to 40 | 130 (58.6) | 24 (88.9) | 0.008 |
| 41 to 59 | 81 (36.5) | 3 (11.1) | ||
| ≥ 60 | 11 (4.9) | 0 | ||
|
| Male | 68 (30.6) | 12 (44.4) | 0.189 |
| Female | 154 (69.4) | 15 (55.6) | ||
|
| White | 29 (13.1) | 1 (11.1) | 1.000 |
| Black | 3 (1.3) | 0 | ||
| Brown | 186 (83.8) | 24 (88.9) | ||
| Indigenous | 1 (0.4) | 0 | ||
| Other | 3 (1.4) | 0 | ||
|
| 3.8 ± 2.3 | 4.6 ± 2.3 | 0.0401 | |
|
| 0 to 2 | 66 (29.7) | 4 (14.8) | 0.140 |
| 3 to 5 | 115 (51.8) | 15 (55.6) | ||
| 6 to 8 | 36 (16.2) | 6 (22.2) | ||
| ≥ 9 | 5 (2.3) | 2 (7.4) | ||
|
| Maculopapular rash | 203 (91.4) | 25 (92.6) | 0.839 |
| Pruritus | 203 (91.4) | 24 (88.9) | 0.659 | |
| Fever | 117 (52.7) | 17 (63.0) | 0.313 | |
| Edema | 150 (67.6) | 18 (66.7) | 0.925 | |
| Arthralgia | 167 (75.2) | 20 (74.1) | 0.896 | |
| Conjunctival hyperemia | 146 (65.8) | 13 (48.2) | 0.072 | |
aOther infections (DENV = 3, CHIKV = 1, parvovirus B19 = 3, measles = 10, HIV = 1, syphilis = 2, EBV + Parvovirus B19 = 1, CMV + Parvovirus B19 = 2, CMV + EBV + Parvovirus B19 = 3, total = 27).
bMean ± standard deviation.
cUnadjusted p-value.
dMann-Whitney test.
eFisher exact test.
fDays from the onset of symptoms until medical attention and collection of laboratory specimens. Minimum value: 1 day in Zika and other infections positive patients. Maximum value: 16 days in Zika positive and 17 days in other infections positive patients.
gPearson Chi-square test.
Prevalence of arboviruses and other infectious causes of rash and co-infections in patients treated at FMT-HVD, Manaus, between February 2018 to May 2019.
| Monoinfections (N = 340) | n (%) |
|---|---|
| ZIKV | 222 (65.3) |
| DENV | 3 (0.9) |
| CHIKV | 1 (0.3) |
| Parvovirus B19 | 3 (0.9) |
| Measles | 10 (2.9) |
| HIV | 1 (0.3) |
| Syphilis | 2 (0.6) |
|
| |
| ZIKV + HIV | 1 (0.3) |
| ZIKV + Measles | 1 (0.3) |
| ZIKV + Parvovirus B19 | 1 (0.3) |
| ZIKV + EBV | 1 (0.3) |
| EBV + Parvovirus B19 | 1 (0.3) |
| CMV + Parvovirus B19 | 2 (0.6) |
| CMV + Syphilis | 1 (0.3) |
| ZIKV + EBV + Parvovirus B19 | 1 (0.3) |
| CMV + EBV + Parvovirus B19 | 3 (1.2) |
| Negative for all infections tested | 86 (25.3) |
EBV: Epstein-Barr; CHIKV: Chikungunya virus; CMV: Cytomegalovirus; DENV: Dengue virus; HIV: Human Immunodeficiency Virus; ZIKV: Zika virus.
Fig 2Rash observed in patients with diagnosis for arboviruses.
(A and B) rash observed on thorax and upper limbs of ZIKV-positive patient. (C and D) peeling rash on face and lower limb edema of a CHIKV-positive patient. (E and F) rash observed on thorax, abdomen and upper limbs of a dengue-positive patient.
Fig 3Rashes observed in patients diagnosed with other infectious diseases in this study.
(A and B) rash observed on thorax and abdomen of an HIV-positive patient. (C and D) rash observed on thorax and upper limbs of a syphilis-positive patient. (E and F) rash observed on anterior and posterior thorax of a measles-positive patient.